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Background: Most patients with moderate and severe chronic obstructive pulmonary disease 
(COPD) receive long-acting bronchodilators (LABA) for symptom control. It is, however, 
unclear if and what drug treatments should be added to LABAs to reduce exacerbations, which 
is an important goal of COPD management. Since current guidelines cannot make strong 
  recommendations yet, our aim was to determine the relative efficacy of existing treatments and 
combinations to reduce the risk for COPD exacerbations.
Methods: We included randomized clinical trials (RCTs) evaluating long-acting β2 agonists 
(LABA), long-acting muscarinic antagonists (LAMA), inhaled glucocorticosterioids (ICS), and 
the phosphodiesterase-4 (PDE4) inhibitor roflumilast, and combinations of these interventions 
in moderate to severe COPD populations. Our primary outcome was the event rate of exacerba-
tions. We conducted a random-effects Bayesian mixed-treatment comparison (MTC) and applied 
several sensitivity analyses. In particular, we confirmed our findings using a binomial MTC 
analysis examining whether a patient experienced at least one exacerbation event or not during 
the trial. We also used an additive assumption to calculate the combined effects of treatments 
that were not included in the systematic review.
Results: Twenty-six studies provided data on the total number of exacerbations and/or the 
mean annual rate of exacerbations among a combined 36,312 patients. There were a total of 10 
treatment combinations in the MTC and 15 in the additive analysis. Compared with all other 
treatments, the combination of roflumilast plus LAMA exhibited the largest treatment effects, 
and had the highest probability (45%) of being the best first-line treatment. This was   consistent 
whether applying the incidence rate analysis or the binomial analysis. When applying the   additive 
assumption, most point estimates suggested that roflumilast may provide additional benefit by 
further reducing exacerbations.
Conclusions: Using various meta-analytic approaches, our study demonstrates that depending 
on the choice of drug, combined treatments offer a therapeutic advantage.
Keywords: exacerbations, MTC analysis, clinical trials, roflumilast
Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and 
mortality throughout the world.1 Predominantly caused by tobacco smoke, which 
causes the airways to narrow, COPD leads to a limitation of the flow of air to and from 
the lungs. This causes shortness of breath. COPD results in an important reduction in 
a patient’s quality of life and places patients at an increased risk for both pulmonary 
and nonpulmonary death.2–5
The course of COPD is characterized by exacerbations, whose frequency and sever-
ity determine much of the patients’ burden from COPD. Since exacerbations impact Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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both on the quality of life of patients and on their prognosis 
an important goal of the COPD management is to prevent 
exacerbations or at least reduce their severity. Long-acting 
bronchodilators such as long-acting β2 agonists (LABA) and 
long-acting antimuscarinic drugs (LAMA) are central in the 
symptomatic management of COPD but they also prevent 
exacerbations by about 20%. Against a backbone of LABAs 
or LAMAs, the addition of inhaled corticosteroids (ICS) or, 
more recently, phosphodiesterase-4 (PDE4) inhibitors may 
provide additional protection, particularly in patients with 
an advanced disease state. PDE4 inhibitors provide a novel 
approach to the treatment of COPD. These drugs exhibit a 
wide range of anti-inflammatory actions.   Roflumilast is the 
only available PDE4 inhibitor and reduces airway inflam-
mation in COPD, as assessed with sputum neutrophil 
and eosinophil counts. Although six randomized trials of 
roflumilast have been completed,6–9 the relative effect of 
roflumilast in addition to established interventions is not 
well understood.
Previous meta-analysis have relied on head-to-head ran-
domized trials to provide evidence of relative effectiveness.10–16 
Head-to-head trials provide evidence when interventions have 
been simultaneously compared. Other approaches, includ-
ing mixed-treatment comparisons, can provide evidence of 
relative effects when interventions have not been evaluated 
directly.15,16 Two mixed-treatment meta-analyses have exam-
ined the comparative effectiveness of interventions,17,18 but 
did not include roflumilast. There is also controversy about 
the application of meta-analysis of COPD exacerbation data 
as original trials may report outcomes heterogeneously.19,20 
The controversy debates whether one should include exac-
erbations rates or a binomial event occurrence whereby 
a patient had at least one exacerbation during the course of 
a randomized, controlled trial (RCT) or not.
We aimed to determine the relative effectiveness of 
LABA, LAMA, PDE4 inhibitors, and ICS in various com-
binations for a specific and clinically important endpoint, 
ie, exacerbations. We conducted a multiple treatment 
  meta-analysis and multiplicative analysis to determine the 
relative effectiveness of these interventions.
Methods
Analysis
To overcome the controversy of whether to apply rates 
or binomial events (ever had an event or not), we applied 
both analyses. Our primary analysis was based on rates 
and then confirmed using the binomial analysis reported as 
relative risks.
Eligibility criteria
We included any published randomized clinical trial evalu-
ating patients with moderate to severe COPD as defined by 
the Global Initiative on Obstructive Lung Disease (GOLD) 
classification, in line with the American Thoracic Society 
and European Respiratory Society (ATS/ERS).21 RCTs had 
to be of at least 24 weeks (6 months) duration. We considered 
any RCT evaluating the following therapeutic interventions: 
LABA (formoterol or salmeterol); LAMA (tiotropium); ICS 
(fluticasone or budesonide); PDE4   inhibitors (roflumilast); 
and combinations of these interventions. Control interven-
tions included these active interventions or placebo. We 
excluded pharmacokinetic studies and proof of concept 
studies.
Primary outcome
The primary outcome of interest for this analysis was exacer-
bations rates reported in the original studies. An exacerbation 
is defined as “sustained worsening of the patient’s condi-
tion, from the stable state and beyond normal day-to-day 
variations, that is acute in onset and necessitates a change 
in regular medication in a patient with underlying COPD”.22 
Where reported, we extracted data on exacerbations as 
moderate and severe. Moderate is considered as “patient 
has an increased need for medication, and he/she feels the 
need to seek   additional medical assistance” and severe as 
“patient/caregiver recognizes obvious and/or rapid deteriora-
tion in condition, requiring hospitalization”.22 In a sensitivity 
analysis, we confirmed these findings using the binomial 
endpoint of a patient having had at least one exacerbation 
event during the course of the trial.
search criteria
Independently, in duplicate, we searched the follow-
ing electronic databases (from inception to September 
2010): MedLine via PubMed; EMBASE; and Cochrane 
CENTRAL. We used the following terms for searching, 
including their MeSH terms: randomized controlled trial; 
controlled clinical trial; randomized; chronic obstructive 
pulmonary disease; long-acting beta agonist (LABA); 
formoterol; salmeterol; long-acting muscarinic antago-
nists (LAMA); tiotropium; inhaled corticosteroids (ICS); 
fluticasone; budesonide; and roflumilast. We searched the 
bibliographies of relevant previous publications. Studies 
were restricted to those published in English. Although 
we read the full manuscripts of any substudies or post-hoc 
evaluations, our primary analyses were based on the main 
published study trial reports.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Data abstraction
Two reviewers abstracted data in duplicate independently 
on the study characteristics, populations, and interventions. 
We extracted data on the primary outcome of interest, 
  exacerbations, according to the primary definition used in 
each study. We extracted data on the number of exacerba-
tions per patient arm and calculated total patient years at risk 
as reported in the article, or if unavailable, by the intention 
to treat principal by multiplying the number of participants 
by the planned study duration. For the binomial evaluation 
of rates, we extracted data on the number of patients having 
had at least one exacerbation in each arm over the course of 
the trial, regardless of how many additional exacerbations 
patients may have experienced.
statistical analyses
We plotted the geometric distribution of the included trials 
with circles representing the interventions and lines denot-
ing the number of trials between interventions.23 We used a 
mixed-treatment comparison (MTC) meta-analysis frame-
work to analyze the data provided by the studies included in 
our systematic review and compare the different treatment 
regimens with respect to the outcomes of interest.24 This 
framework is suitable for meta-analytic situations where 
we wish to assess the relative effects of pairs of treatments 
based on direct and indirect evidence provided by random-
ized clinical trials,24 thereby providing a generalization of 
meta-analysis methods because it allows comparisons of 
agents not addressed within any of the individual primary 
trials. One of the advantages of this framework, from a medi-
cal decision-making viewpoint is that, when conducted in a 
Bayesian setting, it affords the estimation of the probability 
of each treatment being the best with respect to the outcome 
of interest. Another advantage is that this framework can 
accommodate study-level covariates in order to determine 
to what degree these covariates may help explain potential 
heterogeneity in the relative effects of pairs of treatments 
over and above that explained by chance and helps reduce 
the inconsistency in the network of treatments.25
Each of the studies contributed the following data to the 
MTC analyses conducted in this paper: i) the total number of 
exacerbations in COPD experienced in each treatment arm, 
ii) the total number of patient-years at risk per treatment arm, 
and iii) the total number of patients experiencing at least one 
exacerbation event. In order to reflect the fact that individual 
patients could experience multiple exacerbations in COPD 
over the duration of follow-up and that different trials had 
different durations of follow-up, we chose to model the 
expected rates of exacerbations in COPD per person-years. 
This enabled us to express the relative effects of pairs of treat-
ments in terms of rate ratios of exacerbations in COPD.
We used the data supplied by all 26 studies to perform a 
primary MTC analysis, supplemented by a variety of sensitiv-
ity analyses. Our primary MTC analysis focused on comparing 
just the 10 interventions that were included in the 26 studies, 
whereas our secondary MTC analysis aimed to facilitate the 
comparison of all possible interventions obtained by combin-
ing the active treatments (ie, five single interventions plus 10 
combinations of active single   interventions). The sensitivity 
analyses accompanying the primary MTC analysis explored 
the robustness of our   conclusions to changes in the nature of 
the data, the model or the outcome.
The primary MTC analysis used the rates of exacerba-
tions as the outcome of interest and implemented a standard 
random-effects Poisson regression model that did not include 
any covariate, similar to the one considered by Cooper et al.26 
Appendix 1 provides a description of the model implementa-
tion of our primary analysis along with details concerning 
its WinBUGS implementation (MRC Biostatistics Unit, 
Cambridge, UK).
The sensitivity analyses accompanying our primary 
MTC analyses proceeded along the following lines. First, we 
examined a fixed-effects Poisson regression model; second, 
we applied a random-effects logistic regression model to the 
binomial event rates using relative risk as the pooled effect 
size, and third, we examined i) whether or not covariates such 
as severity of COPD exacerbations and study publication year 
could be used to explain the between-study heterogeneity 
in our primary MTC analysis, and ii) whether the results 
produced by the primary MTC analysis were insensitive to 
various choices of Bayesian priors for the between-study 
standard deviation. We also re-run our primary analysis using 
the same data as for the secondary analysis. In the secondary 
analysis, the data for one of the published trials by Calverley 
was replaced with that from a trial unpublished at the time 
of manuscript acceptance that pooled the Calverley trial 
with new data.27 Appendix 1 displays the results of the main 
sensitivity analyses.
While our primary MTC analysis enabled us to derive the 
relative effects of the interventions directly investigated in 
the 26 studies included in our systematic review, it did not 
afford enough flexibility to facilitate comparisons between 
combinations of active treatments not investigated in these 
studies. For instance, given that roflumilast plus LABA was 
directly investigated in one of the 26 studies and LABA plus 
LAMA was directly investigated in two of the 26 studies, Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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the relative effect of roflumilast plus LABA versus LABA 
plus LAMA could easily be derived on the basis of the 
primary MTC analysis. Nevertheless, this analysis did not 
support the derivation of the relative effect of roflumilast plus 
LABA plus LAMA versus LABA plus LAMA, as none of 
the 26 studies utilized in the analysis investigated the effect 
of roflumilast plus LABA plus LAMA relative to that of 
another intervention.
To overcome this limitation of our primary MTC   analysis, 
we conducted a secondary MTC analysis. Just like the 
primary MTC analysis, the secondary MTC analysis used 
the rates of exacerbations as the outcome of interest and 
relied on a random-effects Poisson regression model for 
the   intervention effects. In this model, termed an additive 
main-effects model, each of the single treatments of placebo, 
roflumilast, LABA, LAMA, and ICS was allowed to have a 
different mean effect, denoted by dPlacebo, dRoflumilast, dLABA, dLAMA, 
and dICS, respectively. Furthermore, the effect of each combi-
nation of two or more active treatments (eg, roflumilast plus 
LABA plus LAMA), was expressed as a sum of the relevant 
active component effects, dRoflumilast, dLABA, dLAMA, and dICS, for a 
particular intervention k. So for the intervention roflumilast 
plus LABA plus LAMA, one had dk = dRoflumilast + dLABA + dLAMA. 
More generally, for the intervention k, one had:
dk = dRoflumilast * Ik⊃Roflumilast + dLABA * Ik⊃LABA 
    + dLAMA * Ik⊃LAMA + dICS * Ik⊃ICS,
where the notation dRoflumilast * Ik⊃Roflumilast means that the inter-
vention k included a roflumilast component. (In other words, 
Ik⊃Roflumilast was set to 1 if dk included a roflumilast component 
and 0 otherwise). Our additive main effects model is similar to 
the additive main effects models considered by Welton et al28 
with the difference being that we used rates of exacerbation as 
our outcome, rather than binary or continuous outcomes.
Our primary and secondary MTC analyses assumed that 
1) the study-specific relative treatment effects were different 
yet similar enough to combine from a common population 
and 2) the potential heterogeneity in study-specific relative 
treatment effects was constant across pairwise treatment 
comparisons. Various sensitivity analysis models additionally 
assumed that potential heterogeneity in study-specific relative 
treatment effects could not be explained by chance alone and 
investigated to what extent a study-specific covariate would 
help explain the excess between-study variation. These mod-
els assumed that the effect of the covariate of interest on the 
relative effects of pairs of treatments was common across all 
pairwise treatment comparisons. All   models took into account 
the correlation structure induced by the   multi-arm trials, 
except for the random-effects logistic regression model used 
in the sensitivity analysis relying on binomial event rates.
For both the primary and secondary MTC analyses, we 
produced estimated rate ratios of exacerbations in COPD per 
patient-years and corresponding 95% confidence intervals for 
each pairwise treatment comparison. We also produced esti-
mates of the absolute effect of each treatment – expressed as 
mean exacerbations per patient-years – as well as estimated 
probabilities that each treatment is best (in the sense of being 
associated with the lowest rate of exacerbations in COPD 
per patient-years).
We produced similar quantities for the sensitivity analy-
ses utilizing the rates of exacerbations as an outcome. For 
the sensitivity analyses involving binomial event rates, we 
produced estimated relative risks and corresponding 95% 
confidence intervals for each pairwise treatment comparison, 
along with estimates of the absolute effect of each treatment 
and estimated probabilities that each treatment is best.
For all MTC analyses, we measured the goodness of fit of 
each of the models to the data by calculating the residual devi-
ance and comparing it against the number of unconstrained 
data points, where the number of unconstrained data points 
was obtained by summing up the number of study arms 
across all studies included in our analyses. Given a model, 
the residual deviance is defined as the difference between 
the deviance for the fitted model and the deviance for the 
saturated model, where the deviance measures the fit of 
the model to the unconstrained data points using the appro-
priate likelihood function (eg, Poisson likelihood, binomial 
likelihood). Under the null hypothesis that the model provides 
an adequate fit to the data, the residual deviance is expected 
to have a mean equal to the number of unconstrained data 
points.26 We compared the fits of the models using the devi-
ance information criterion (DIC). A model with its DIC being 
at least three points lower than a second model is considered 
to have a better fit.29
We fitted all models via a Bayesian Markov chain Monte 
Carlo (MCMC) method, as implemented in the freely avail-
able software WinBUGS (Version 1.4; MRC Biostatistics 
Unit). Given each model, we used noninformative normal 
priors for all model parameters except for the between-study 
standard deviation, for which we used an noninformative uni-
form prior (range 0–10). For each model, we ran two MCMC 
chains for 100,000 iterations with a thin parameter of 10 
after a ‘burn-in’ of 20,000 in order to ensure convergence of 
the MCMC sampler. We conducted posterior inference after 
discarding the ‘burn-in’ iterations, thereby relying on 20,000 
samples. The results of the model fits are also presented in Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
111
Pharmacotherapies for COPD
Appendix 1. We checked the MTC rate outcomes to standard 
pairwise random-effects meta-analysis for consistency.30
Results
inclusion of studies
Twenty-six studies met our inclusion criteria for our primary 
analysis.6–9,31–54 Of the four studies each reporting on two 
clinical trials, three pooled the trial data together,6,34,39 and 
one reported each trial separately.7
Thirty clinical trials included in two previous meta-
analyses assessing COPD drugs17,55 were excluded 
from our study because they did not meet our inclusion 
criteria.56–83 Eighteen of these clinical trials were excluded 
because the treatment duration was less than 24 weeks in 
length.56,59,60,62–65,67,69,70,72,74,75,77,79–82 Eleven were excluded 
because they assessed treatments that were not of 
interest,57,61,66,76,83 they did not provide sufficient detail on 
exacerbations,54,68,71,73 they were published in a language 
other than English,58 or they examined the effect of drug 
discontinuation.78 One additional clinical trial84 included in 
the previous meta-analyses was excluded from our study 
because the data was later republished together with another 
trial.34 We considered the data from both trials as published 
in the second manuscript.34 Five clinical trials found in our 
comparable search were also excluded because they did not 
provide sufficient detail on exacerbations2–4 or the treat-
ment duration was less than 24 weeks in length.5,10 Figure 1 
  displays the study flow diagram.
All clinical trials that met our inclusion criteria reported 
COPD exacerbations following treatment. All clinical 
  trials recruited patients with a forced expiratory volume in 
1 second (FEV1) ,80% of the predicted value. Duration of 
treatment ranged from 24 weeks to 4 years. All clinical tri-
als permitted the use of background therapy and/or rescue 
therapy. Twenty of the randomized trials used a placebo 
control,6,8,9,33–42,45–51,54 12 assessed LAMA,7,31,34,39,40,42,45,47,50–53   
13 assessed LABA,7,32,34,36–38,41,43,44,48,49,52,54 7 assessed 
ICS,33,35–38,48,49 3 assessed roflumilast,6,8,9 and 13 assessed com-
binations of these drugs: 2 LAMA plus LABA,31,52 8 LABA 
plus ICS,32,36–38,43,44,49,53 1 LAMA plus LABA plus ICS,31 
1 LAMA plus roflumilast,7 and 1 LABA plus roflumilast.7
Twenty-six studies provided data on the total number of 
exacerbations and/or the mean annual rate of exacerbations 
among a combined 36,312 patients.6–9,31,32,34–40,42–51,53,54 These 
data contributed to our first analysis of total exacerbations. 
Table 1A provides the characteristics of these clinical trials. An 
additional three studies33,41,52 provided data on the   proportion 
of patients with at least one exacerbation allowing a combined 
36,657 patients. These data contributed to our second analy-
sis of the number of patients with at least one exacerbation. 
Table 1B provides the characteristics of these clinical trials.
The network of treatments compared is displayed in 
Figure 2. The treatments form a closed network, which is 
amenable to MTC analyses.
reporting quality
We assessed the quality of reporting specific methodologi-
cal items. Eighteen reported on how randomization was 
achieved,6–9,31–33,35,36,38,41,43,45,46,48,50,51,53 16 reported on con-
cealment of allocation,6–9,31–33,35,36,38,44–46,48,50,53 14 reported on 
blinding,6–9,31,33,35,36,38,40,45,46,50,54 20 were assumed as intention-
to-treat time periods,6–9,32,33,34,36–42,45,46,48,49,52,53 and 20 had 
greater than 20% drop-outs.6,9,31,32,35–40,42,43,45,47–51,53,54
results of the primary MTC analysis
The random-effects Poisson regression model considered 
in our primary MTC analysis provides a reasonable fit to 
the data, as evidenced by the low residual deviance (67.61) 
compared to the unconstrained number of data points (62).
Table 2 reports the estimated rate ratios of exacerbations 
and 95% confidence intervals for the relative effects of the 
10 interventions for management of COPD investigated in 
the 26 studies. Figure 3 displays these results graphically. 
As can be seen from Table 2 and the direct (head-to-head) 
evaluations reported in Appendix 1 (Tables 7 and 8), the 
studies provide consistent results.
62 studies identified:
44 from prior meta-analyses
18 from comparable searches
36 studies excluded:
20 duration was <24 weeks
7 did not provide sufficient data
5 studies had ineligible treatments
1 study excluded as could not be
translated
1 examined the effect of drug
discontinuation
2 data subsequently published in
included trials
26 studies included in
primary analysis
Figure 1 Flow diagram of included studies.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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b
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c
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c
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t
.
 
A
c
u
t
e
 
m
o
d
e
r
a
t
e
 
a
n
d
 
s
e
v
e
r
e
 
e
x
a
c
e
r
b
a
t
i
o
n
s
 
t
r
e
a
t
e
d
 
w
i
t
h
 
s
y
s
t
e
m
i
c
 
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
 
a
n
d
/
o
r
 
a
n
t
i
b
i
o
t
i
c
s
.
4
4
 
w
e
e
k
s
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r
e
s
p
i
r
a
t
o
r
y
 
c
e
n
t
e
r
s
 
i
n
 
g
e
r
m
a
n
y
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o
w
r
i
e
 
e
t
 
a
l
 
2
0
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P
l
a
c
e
b
o
 
T
i
o
t
r
o
p
i
u
m
 
1
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µ
g
 
o
n
c
e
 
d
a
i
l
y
F
E
V
1
 
,
 
8
0
%
D
e
fi
n
e
d
 
a
s
 
t
h
e
 
p
r
e
s
e
n
c
e
,
 
f
o
r
 
$
2
 
d
a
y
s
 
c
o
n
s
e
c
u
t
i
v
e
l
y
,
 
o
f
 
a
n
 
i
n
c
r
e
a
s
e
 
i
n
 
a
n
y
 
t
w
o
 
m
a
j
o
r
 
s
y
m
p
t
o
m
s
 
(
d
y
s
p
n
e
a
,
 
s
p
u
t
u
m
 
p
u
r
u
l
e
n
c
e
,
 
a
n
d
 
s
p
u
t
u
m
 
v
o
l
u
m
e
)
 
o
r
 
i
n
 
o
n
e
 
m
a
j
o
r
 
a
n
d
 
o
n
e
 
m
i
n
o
r
 
s
y
m
p
t
o
m
 
(
w
h
e
e
z
e
,
 
s
o
r
e
 
t
h
r
o
a
t
,
 
c
o
u
g
h
,
 
a
n
d
 
s
y
m
p
t
o
m
s
 
o
f
 
a
 
c
o
m
m
o
n
 
c
o
l
d
)
.
E
x
c
e
p
t
 
f
o
r
 
o
t
h
e
r
 
a
n
t
i
c
h
o
l
i
n
e
r
g
i
c
s
,
 
p
u
l
m
o
n
a
r
y
 
d
r
u
g
s
 
w
e
r
e
 
p
e
r
m
i
t
t
e
d
.
1
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o
n
t
h
s
i
n
g
l
e
 
c
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n
t
e
r
F
e
r
g
u
s
o
n
 
e
t
 
a
l
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a
l
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r
o
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u
t
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n
e
 
p
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a
t
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µ
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t
w
i
c
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d
a
i
l
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E
V
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5
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%
D
e
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n
e
d
 
a
s
 
t
h
e
 
w
o
r
s
e
n
i
n
g
 
o
f
 
t
w
o
 
o
r
 
m
o
r
e
 
m
a
j
o
r
 
s
y
m
p
t
o
m
s
 
o
r
 
o
n
e
 
m
a
j
o
r
 
a
n
d
 
o
n
e
 
m
i
n
o
r
 
s
y
m
p
t
o
m
 
f
o
r
 
t
w
o
 
o
r
 
m
o
r
e
 
c
o
n
s
e
c
u
t
i
v
e
 
d
a
y
s
.
O
r
a
l
 
c
o
r
t
i
c
i
s
t
e
r
o
i
d
s
 
a
n
d
 
a
n
t
i
b
i
o
t
i
c
s
 
w
e
r
e
 
a
l
l
o
w
e
d
 
f
o
r
 
t
h
e
 
a
c
u
t
e
 
t
r
e
a
t
m
e
n
t
 
o
f
 
e
x
a
c
e
r
b
a
t
i
o
n
s
.
1
2
 
m
o
n
t
h
s
9
4
 
r
e
s
e
a
r
c
h
 
s
i
t
e
s
 
i
n
 
t
h
e
 
U
n
i
t
e
d
 
s
t
a
t
e
s
 
a
n
d
 
C
a
n
a
d
a
T
a
s
h
k
i
n
 
e
t
 
a
l
 
2
0
0
8
3
0
0
6
 
2
9
8
7
P
l
a
c
e
b
o
 
T
i
o
t
r
o
p
i
u
m
 
1
8
 
µ
g
 
o
n
c
e
 
d
a
i
l
y
F
E
V
1
 
,
 
7
0
%
D
e
fi
n
e
d
 
a
s
 
a
n
 
i
n
c
r
e
a
s
e
 
i
n
 
o
r
 
t
h
e
 
n
e
w
 
o
n
s
e
t
 
o
f
 
.
1
 
r
e
s
p
i
r
a
t
o
r
y
 
s
y
m
p
t
o
m
 
(
c
o
u
g
h
,
 
s
p
u
t
u
m
,
 
s
p
u
t
u
m
 
p
u
r
u
l
e
n
c
e
,
 
w
h
e
e
z
i
n
g
,
 
o
r
 
d
y
s
p
n
e
a
)
 
l
a
s
t
i
n
g
 
$
3
 
d
a
y
s
 
a
n
d
 
r
e
q
u
i
r
i
n
g
 
a
n
 
a
n
t
i
b
i
o
t
i
c
 
o
r
 
c
o
r
t
i
c
o
s
t
e
r
o
i
d
.
A
l
l
 
r
e
s
p
i
r
a
t
o
r
y
 
m
e
d
i
c
a
t
i
o
n
 
a
l
l
o
w
e
d
,
 
e
x
c
e
p
t
 
i
n
h
a
l
e
d
 
a
n
t
i
c
h
o
l
i
n
e
r
g
i
c
 
d
r
u
g
s
.
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o
n
t
h
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c
e
n
t
e
r
s
 
i
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u
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t
r
i
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n
e
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a
l
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a
c
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i
o
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o
p
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µ
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n
c
e
 
d
a
i
l
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E
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2
0
%
–
7
0
%
D
e
fi
n
e
d
 
a
s
 
a
 
s
u
s
t
a
i
n
e
d
 
w
o
r
s
e
n
i
n
g
 
o
f
 
t
h
e
 
p
a
t
i
e
n
t
’
s
 
C
O
P
D
 
(
f
r
o
m
 
t
h
e
 
s
t
a
b
l
e
 
s
t
a
t
e
 
a
n
d
 
b
e
y
o
n
d
 
n
o
r
m
a
l
 
d
a
y
-
t
o
-
d
a
y
 
v
a
r
i
a
t
i
o
n
)
 
t
h
a
t
 
w
a
s
 
a
c
u
t
e
 
i
n
 
o
n
s
e
t
 
a
n
d
 
n
e
c
e
s
s
i
t
a
t
e
d
 
a
 
c
h
a
n
g
e
 
i
n
 
r
e
g
u
l
a
r
 
m
e
d
i
c
a
t
i
o
n
.
U
s
e
 
o
f
 
t
h
e
o
p
h
y
l
l
i
n
e
 
p
r
e
p
a
r
a
t
i
o
n
s
,
 
m
u
c
o
l
y
t
i
c
s
,
 
i
n
h
a
l
e
d
 
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
,
 
a
n
d
 
o
r
a
l
 
s
t
e
r
o
i
d
s
 
w
e
r
e
 
a
l
l
o
w
e
d
 
i
f
 
d
o
s
a
g
e
 
w
a
s
 
s
t
a
b
i
l
i
z
e
d
 
f
o
r
 
6
 
o
r
 
m
o
r
e
 
w
e
e
k
s
 
b
e
f
o
r
e
 
s
t
u
d
y
 
e
n
t
r
y
.
 
O
n
e
 
1
0
-
d
a
y
 
c
o
u
r
s
e
 
o
f
 
o
r
a
l
 
s
t
e
r
o
i
d
s
 
w
a
s
 
p
e
r
m
i
t
t
e
d
 
f
o
r
 
t
r
e
a
t
m
e
n
t
 
e
x
a
c
e
r
b
a
t
i
o
n
s
.
 
A
n
t
i
b
i
o
t
i
c
s
 
c
o
u
l
d
 
a
l
s
o
 
b
e
 
u
s
e
d
 
f
o
r
 
t
r
e
a
t
m
e
n
t
 
o
f
 
e
x
a
c
e
r
b
a
t
i
o
n
s
.
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n
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s
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c
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c
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b
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c
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c
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a
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l
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u
c
t
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c
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c
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T
i
o
t
r
o
p
i
u
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µ
g
 
 
o
n
c
e
 
d
a
i
l
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F
E
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5
0
%
D
e
fi
n
e
d
 
a
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s
y
m
p
t
o
m
s
 
t
h
a
t
 
r
e
q
u
i
r
e
d
 
t
r
e
a
t
m
e
n
t
 
w
i
t
h
 
o
r
a
l
 
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
 
a
n
d
/
o
r
 
a
n
t
i
b
i
o
t
i
c
s
 
o
r
 
r
e
q
u
i
r
e
d
 
h
o
s
p
i
t
a
l
i
z
a
t
i
o
n
.
s
h
o
r
t
 
a
c
t
i
n
g
 
i
n
h
a
l
e
d
 
b
e
t
a
-
a
g
o
n
i
s
t
s
 
f
o
r
 
r
e
l
i
e
f
 
t
h
e
r
a
p
y
 
a
n
d
 
s
t
a
n
d
a
r
d
i
z
e
d
 
s
h
o
r
t
 
c
o
u
r
s
e
s
 
o
f
 
o
r
a
l
 
s
y
s
t
e
m
i
c
 
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
 
a
n
d
/
o
r
 
a
n
t
i
b
i
o
t
i
c
s
 
w
h
e
r
e
 
i
n
d
i
c
a
t
e
d
 
f
o
r
 
t
r
e
a
t
m
e
n
t
 
o
f
 
e
x
a
c
e
r
b
a
t
i
o
n
s
.
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c
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c
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µ
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w
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i
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5
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D
e
fi
n
e
d
 
a
s
 
t
h
e
 
w
o
r
s
e
n
i
n
g
 
o
f
 
t
w
o
 
o
r
 
m
o
r
e
 
m
a
j
o
r
 
s
y
m
p
t
o
m
s
 
o
r
 
1
 
m
a
j
o
r
 
a
n
d
 
o
n
e
 
m
i
n
o
r
 
s
y
m
p
t
o
m
 
f
o
r
 
t
w
o
 
o
r
 
m
o
r
e
 
c
o
n
s
e
c
u
t
i
v
e
 
d
a
y
s
.
A
l
b
u
t
e
r
o
l
 
w
a
s
 
p
r
o
v
i
d
e
d
 
a
s
-
n
e
e
d
e
d
.
 
i
p
r
a
t
r
o
p
i
u
m
 
w
a
s
 
p
e
r
m
i
t
t
e
d
 
t
h
r
o
u
g
h
o
u
t
 
t
h
e
 
s
t
u
d
y
.
 
O
r
a
l
 
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
 
a
n
d
 
a
n
t
i
b
i
o
t
i
c
s
 
w
e
r
e
 
a
l
l
o
w
e
d
 
f
o
r
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
o
f
 
e
x
a
c
e
r
b
a
t
i
o
n
s
.
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n
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s
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c
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n
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r
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h
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n
i
t
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n
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C
a
n
a
d
a
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a
l
v
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r
l
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e
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n
d
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c
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o
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c
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e
 
d
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s
y
m
p
t
o
m
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r
e
q
u
i
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n
g
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o
r
t
i
c
o
s
t
e
r
o
i
d
s
.
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e
v
e
r
e
 
e
x
a
c
e
r
b
a
t
i
o
n
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w
e
r
e
 
d
e
fi
n
e
d
 
a
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s
y
m
p
t
o
m
s
 
r
e
q
u
i
r
i
n
g
 
h
o
s
p
i
t
a
l
i
z
a
t
i
o
n
 
o
r
 
d
e
a
t
h
.
s
h
o
r
t
-
a
c
t
i
n
g
 
b
e
t
a
 
2
-
a
g
o
n
i
s
t
s
 
a
s
 
n
e
e
d
e
d
.
 
L
o
n
g
-
a
c
t
i
n
g
 
a
n
d
 
s
h
o
r
t
-
a
c
t
i
n
g
 
a
n
t
i
c
h
o
l
i
n
e
r
g
i
c
 
d
r
u
g
s
 
a
t
 
s
t
a
b
l
e
 
d
o
s
e
s
.
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c
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e
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M
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c
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o
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h
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n
e
e
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o
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a
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i
n
c
r
e
a
s
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i
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r
e
s
c
u
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m
e
d
i
c
a
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i
o
n
 
o
f
 
a
t
 
l
e
a
s
t
 
t
h
r
e
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p
u
f
f
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p
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a
y
 
o
n
 
a
t
 
l
e
a
s
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w
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o
n
s
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c
u
t
i
v
e
 
d
a
y
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.
 
M
o
d
e
r
a
t
e
 
e
x
a
c
e
r
b
a
t
i
o
n
s
 
w
e
r
e
 
d
e
fi
n
e
d
 
a
s
 
t
h
e
 
n
e
e
d
 
f
o
r
 
o
r
a
l
 
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
 
(
n
o
t
 
a
n
t
i
b
i
o
t
i
c
s
)
.
 
S
e
v
e
r
e
 
e
x
a
c
e
r
b
a
t
i
o
n
s
 
w
e
r
e
 
d
e
fi
n
e
d
 
a
s
 
t
h
e
 
n
e
e
d
 
f
o
r
 
t
r
e
a
t
m
e
n
t
 
i
n
 
h
o
s
p
i
t
a
l
 
o
r
 
d
e
a
t
h
.
B
e
s
i
d
e
s
 
t
i
o
t
r
o
p
i
u
m
,
 
n
o
 
i
n
h
a
l
e
d
 
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
,
 
s
h
o
r
t
a
c
t
i
n
g
 
a
n
t
i
c
h
o
l
i
n
e
r
g
i
c
 
d
r
u
g
s
,
 
o
t
h
e
r
 
l
o
n
g
-
a
c
t
i
n
g
 
b
r
o
n
c
h
o
d
i
l
a
t
o
r
 
d
r
u
g
s
,
 
t
h
e
o
p
h
y
l
l
i
n
e
,
 
o
r
 
o
t
h
e
r
 
r
e
s
p
i
r
a
t
o
r
y
 
d
r
u
g
s
 
w
e
r
e
 
a
l
l
o
w
e
d
.
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Table 3 reports the absolute treatment effects correspond-
ing to the 10 interventions, expressed as mean exacerbations 
per patient-years. The findings in this table favor both current 
intensive therapy (ICS plus LABA plus LAMA) and also the 
addition of roflumilast to this therapy.
Table 4 reports the probability that each treatment is best 
obtained on the basis of our primary analysis. Each column 
represents the possibility of first-line treatment, second-line, 
and so on. According to Table 4, the highest probability of 
reductions in exacerbations is found from the combination 
of roflumilast plus a LAMA.
results of the additive MTC analysis
Our additive main effects model considered in our sec-
ondary MTC analysis provides adequate fit to the data, as 
evidenced by the low residual deviance (69.56) compared 
to the unconstrained number of data points (62) (slightly 
lower than that of the model considered in our primary MTC 
analysis, but still within a 3-point difference), suggesting 
that this model is comparable to the one used in our primary 
MTC analysis.
Table 5 reports the estimated rate ratios of exacerba-
tions and 95% confidence intervals for the relative effects of 
specific pairs of treatment combinations. Each pair is of the 
form “comparator plus roflumilast” vs “comparator”, with 
“comparator” being one of the combinations LABA plus ICS, 
LABA plus ICS plus LAMA, and LABA plus LAMA.
Table 6 reports the absolute treatment effects correspond-
ing to the 15 interventions (ie, 5 single treatments plus 10 
Roflumilast +
LABA
LABA
LAMA
ICS +
LAMA +
LABA
LABA +
LAMA
Roflumilast
Roflumilast +
LAMA
1
1 11
1
1
1
7
7
8
4 3
6
3
4
ICS
ICS + LABA
Placebo
Figure  2  Diagram  displaying  the  network  of  10  treatments  involved  in  the 
MTC analyses of the COPD data. Each treatment is a node in the network. The 
links between nodes are used to indicate a direct comparison between pairs of 
treatments. The numbers shown along the link lines indicate the number of trials 
comparing pairs of treatments head-to-head.
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  iCs,  inhaled 
corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic 
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Table 2 Estimated rate ratios and 95% Ci for the relative effects 
of pairs of treatments, produced by the random-effects MTC 
model without covariates
Treatment vs comparator Random-effects MTC 
model
Rate ratio 95% CI
Roflumilast vs placebo 0.85 (0.72, 0.97)
LABA vs placebo 0.84 (0.75, 0.93)
LAMA vs placebo 0.74 (0.66, 0.81)
iCs vs placebo 0.80 (0.71, 0.90)
Roflumilast + LABA vs placebo 0.67 (0.48, 0.91)
Roflumilast + LAMA vs placebo 0.62 (0.44, 0.85)
LABA + LAMA vs placebo 0.80 (0.56, 1.12)
iCs + LABA vs placebo 0.69 (0.61, 0.77)
iCs + LAMA + LABA vs placebo 0.68 (0.47, 0.95)
LABA vs roflumilast 0.98 (0.80, 1.19)
LAMA vs roflumilast 0.87 (0.71, 1.05)
ICS vs roflumilast 0.94 (0.76, 1.15)
Roflumilast + LABA vs roflumilast 0.79 (0.54, 1.12)
Roflumilast + LAMA vs roflumilast 0.73 (0.50, 1.04)
LABA + LAMA vs roflumilast 0.94 (0.63, 1.36)
iCs + LABA vs roflumilast 0.81 (0.66, 0.99)
iCs + LAMA + LABA vs roflumilast 0.80 (0.53, 1.16)
LAMA vs LABA 0.88 (0.77, 1.01)
iCs vs LABA 0.96 (0.84, 1.09)
Roflumilast + LABA vs LABA 0.80 (0.59, 1.08)
Roflumilast + LAMA vs LABA 0.75 (0.52, 1.03)
LABA + LAMA vs LABA 0.96 (0.66, 1.35)
iCs + LABA vs LABA 0.82 (0.74, 0.92)
iCs + LAMA + LABA vs LABA 0.82 (0.56, 1.15)
iCs vs LAMA 1.09 (0.93, 1.26)
Roflumilast + LABA vs LAMA 0.91 (0.64, 1.25)
Roflumilast + LAMA vs LAMA 0.84 (0.61, 1.14)
LABA + LAMA vs LAMA 1.09 (0.77, 1.49)
iCs + LABA vs LAMA 0.94 (0.81, 1.07)
iCs + LAMA + LABA vs LAMA 0.92 (0.66, 1.28)
Roflumilast + LABA vs iCs 0.84 (0.60, 1.15)
Roflumilast + LAMA vs iCs 0.78 (0.54, 1.08)
LABA + LAMA vs iCs 1.01 (0.69, 1.42)
iCs + LABA vs iCs 0.86 (0.76, 0.98)
iCs + LAMA + LABA vs iCs 0.86 (0.58, 1.21)
Roflumilast + LAMA vs roflumilast + LABA 0.95 (0.58, 1.46)
LABA + LAMA vs roflumilast + LABA 1.23 (0.74, 1.90)
iCs + LABA vs roflumilast + LABA 1.05 (0.75, 1.43)
LAMA + iCs + LABA vs roflumilast + LABA 1.04 (0.63, 1.63)
LABA + LAMA vs roflumilast + LAMA 1.32 (0.82, 2.03)
iCs + LABA vs roflumilast + LAMA 1.14 (0.80, 1.58)
iCs + LAMA + LABA vs roflumilast + LAMA 1.12 (0.70, 1.72)
iCs + LABA vs LABA + LAMA 0.88 (0.61, 1.24)
iCs + LAMA + LABA vs LABA + LAMA 0.86 (0.61, 1.18)
iCs + LAMA + LABA vs iCs + LABA 0.99 (0.68, 1.40)
Notes: A rate ratio smaller (larger) than 1 indicates that the treatment is associated 
with a reduction (increase) in the rate of exacerbations in COPD relative to the 
comparator. This reduction (increase) is statistically significant at the 5% level only if 
the upper end (lower end) of the associated 95% Ci is less than (larger than) 1.
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary 
disease;  iCs,  inhaled  corticosteroids;  LABA,  long-acting  beta  agonists;  LAMA, 
  long-acting antimuscarinic drugs; MTC, mixed-treatment comparison.
combinations of active treatments), expressed as mean 
exacerbations per patient-years. The findings in this table 
favor both current intensive therapy (ICS plus LABA plus 
LAMA) and also the addition of roflumilast to this therapy 
(roflumilast plus ICS plus LABA plus LAMA).
Table 7 reports the probability that each treatment is best, 
obtained on the basis of our secondary analysis. The highest 
probability of reductions in exacerbations is found from the 
combination of roflumilast and the current intensive therapy 
(roflumilast plus ICS plus LABA plus LAMA). All data and 
output from this model are available from the authors upon 
request.
results of the sensitivity analyses
Our first sensitivity analysis replaced the random-effects 
  Poisson regression model used in the primary MTC analysis 
with a fixed-effect Poisson regression model. The results 
of this sensitivity analysis can be found in Appendix 1 
  (Appendix Tables 1–3). In particular, these results suggest 
that the fixed-effect and random-effects analyses provide 
consistent finding. However, the residual deviance associ-
ated with the model employed in the fixed-effect analysis is 
considerably higher (189.00) than that associated with the 
model used in the random-effects analysis, indicating 
that the fixed effects model provides a questionable fit to 
the data.
Appendix Tables 4–6 and 8 present the findings of our 
second sensitivity analysis examining the binomial event 
of ever having an exacerbation event within the intention 
to treat population over the study period. We found consis-
tent effects between the primary MTC analysis using rates 
of exacerbation and the current sensitivity analysis using 
binomial outcomes. This strengthens the inference about the 
credibility of the analysis and the relative treatment effects 
of the interventions. Appendix Table 6 provides similar prob-
abilities that each treatment is best as first line therapy. The 
results of the sensitivity analyses examining the inclusion of 
previously unpublished roflumilast data (M-111 trial)27 are 
presented in Appendix Tables 9–12.
The results of the remaining sensitivity analyses are 
omitted in the interest of saving space. These analyses 
found that the choice of prior for the between-study stan-
dard deviation did not influence the outcome of our primary 
MTC analysis. Also, disease severity and study publication 
year were found to be insignificant modifiers of the relative 
treatment effects produced by the random-effects Poisson 
regression model. This data is available from the authors 
upon request.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Figure 3 Comparisons of all 10 different treatments for management of COPD. Rate ratios and associated 95% confidence intervals were obtained from a random-effects 
MTC model without covariates.
Abbreviations: COPD, chronic obstructive pulmonary disease; iCs, inhaled corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic drugs; 
MTC, mixed-treatment comparison.
Table 3 Absolute treatment effects corresponding to the 10 
treatments for the management of COPD as derived from the 
primary analysis
Treatment Absolute treatment effect 95% CI
Placebo 1.21  (1.17, 1.24)
Roflumilast 1.03  (0.87, 1.21)
LABA 1.01  (0.90, 1.11)
LAMA 0.89  (0.80, 0.98)
iCs 0.96  (0.85, 1.08)
Roflumilast + LABA 0.81  (0.58, 1.10)
Roflumilast + LAMA 0.75  (0.53, 1.02)
LABA + LAMA 0.97  (0.67, 1.34)
iCs + LABA 0.83  (0.73, 0.93)
iCs + LAMA + LABA 0.82  (0.57, 1.15)
Note: Absolute treatment effects are expressed as mean exacerbations experienced 
per patient per patient-year.
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  iCs,  inhaled 
corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic 
drugs; MTC, mixed-treatment comparison.
Discussion
Our study demonstrates that there are small differing 
treatment effects according to the choice of treatment com-
binations chosen. In our analysis, combinations treatments 
demonstrated the largest probability of the largest therapeutic 
effects. Using an additive main effects analysis, whereby we 
create combinations that have not been compared together in 
the trials, we demonstrate that new combinations that include 
roflumilast appear to offer comparable treatment options to 
reduce the risk for exacerbations.
To our knowledge, our analysis is the most up to date 
analysis of interventions recommended in the GOLD and 
ATS/ERS guidelines for the treatment of COPD.21 There 
are, of course, other treatments used in COPD, ranging from 
behavioral therapies to other pharmacotherapies. As with any Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Table 4 Probability each of the 10 treatments for management of COPD is best, obtained on the basis of the random-effects 
MTC model without covariates
Treatment P*1 P2 P3 P4 P5 P6 P7 P8 P9 P10
Placebo 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.012 0.113 0.875
Roflumilast 0.001 0.004 0.010 0.026 0.052 0.103 0.168 0.238 0.372 0.027
LABA 0.000 0.000 0.002 0.008 0.040 0.117 0.259 0.354 0.218 0.001
LAMA 0.001 0.026 0.110 0.272 0.332 0.199 0.048 0.010 0.002 0.000
iCs 0.001 0.004 0.019 0.060 0.139 0.246 0.308 0.165 0.059 0.000
Roflumilast + LABA 0.244 0.231 0.155 0.114 0.082 0.069 0.042 0.032 0.024 0.007
Roflumilast + LAMA 0.453 0.224 0.130 0.071 0.045 0.032 0.018 0.015 0.010 0.002
LABA + LAMA 0.025 0.066 0.096 0.096 0.104 0.129 0.102 0.124 0.178 0.081
iCs + LABA 0.056 0.218 0.322 0.238 0.121 0.041 0.004 0.000 0.000 0.000
iCs + LAMA + LABA 0.219 0.226 0.157 0.115 0.086 0.065 0.049 0.050 0.026 0.008
Note: P1–P10 refers to probability that each is 1st, 2nd, …, k best.
Abbreviations: COPD, chronic obstructive pulmonary disease; iCs, inhaled corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic drugs; MTC, 
mixed-treatment comparison.
Table 5 Estimated rate ratios and 95% CI for the effects of specific pairs of treatment combinations, produced by the additive main 
effects model considered in our secondary MTC analysis
Treatment vs comparator Additive main effects model
Rate ratio 95% CI
LABA plus ICS plus roflumilast vs LABA plus ICS 0.84 (0.74, 0.95)
LABA plus ICS plus LAMA vs LABA plus ICS plus roflumilast 0.89 (0.75, 1.03)
LABA plus ICS plus LAMA plus roflumilast vs LABA plus ICS plus LAMA 0.84 (0.74, 0.95)
LAMA plus LABA plus roflumilast vs LABA plus LAMA 0.84 (0.74, 0.95)
LAMA plus LABA plus roflumilast vs LAMA plus LABA plus ICS  1.00 (0.85, 1.13)
Notes: A rate ratio smaller (larger) than 1 indicates that the treatment is associated with a reduction (increase) in the rate of exacerbations in COPD relative to the 
comparator. This reduction (increase) is statistically significant at the 5% level only if the upper end (lower end) of the associated 95% CI is less than (larger than) 1.
Abbreviations: COPD, chronic obstructive pulmonary disease; iCs, inhaled corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic drugs; MTC, 
mixed-treatment comparison.
research study, we set out our study questions, interventions 
of interest and populations a priori. We believe that our study 
findings should be of relevance to physicians working with 
pharmacotherapies and any recommendations for treatment 
should go hand in hand with individual patient advice tailored 
to the patient’s situation.
Our findings represent an update of two previously pub-
lished mixed treatment comparisons.17,55 Our findings are 
similar to these previous reviews, but differ in two important 
ways. First, neither review included PDE4 inhibitors, the 
interventions that appeared most favorable in our analysis. 
Second, both reviews examined exacerbations as a binomial 
outcome of whether a patient ever had an exacerbation or 
not. This outcome is problematic depending on the study 
population. For example, to take an extreme example, in a 
population enrolling very severe patients we would expect 
all patients to have at least one exacerbation, thus the study 
would find no treatment effect even if the trial intervention 
importance reduced the frequency of exacerbations.
As with any analysis, there are limitations to consider 
when interpreting our analysis. We combined exacerbation 
events across trials that may have differed in terms of patient 
populations, exacerbation definitions, and study design 
  features. Indeed, this issue applies to all meta-analyses and we 
considered a priori whether it was appropriate to pool trials 
and considered it appropriate.85 Despite the large number of 
patients included in the trials, power to differentiate across 
interventions is potentially an issue. Indirect comparisons 
typically require four times the amount of data as a direct 
comparison and in our analysis we had several comparisons 
that had only one trial in them. Thus, it is possible that we 
were unable to identify significant effects where they may 
exist. The MTC approach aims to borrow power from other 
studies that use comparable interventions in their study arms, 
regardless of whether the data from all treatment arms can be 
utilized.86 We searched thoroughly for relevant clinical trials 
to include, but it is possible we have missed unpublished 
studies. Strengths of our study include our extensive analysis 
that examined the impact of differing strategies of analysis 
on the final outcomes. Our sensitivity analyses examined 
both time period of publication and severity of patients and 
found similar treatment effects regardless of these issues. Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
121
Pharmacotherapies for COPD
We applied both exacerbation rates and the outcome of ever 
having at least one event in our analyses and found almost 
identical effects. To our knowledge, this is the first COPD 
meta-analysis to examine this issue and it is reassuring that 
the findings are similar.
We considered a flexible framework for comparing com-
peting interventions by allowing for the possibility that the 
total effect of a combination of treatments is equal to the 
sum of the effects of the components entering this combina-
tion. This additive assumption may be untenable in situa-
tions where particular pairs of components may have either 
bigger (synergistic) or smaller (antagonistic) effects than 
would be expected from the sum of their effects alone. The 
sparsity of our data prevented us from relaxing the additivity 
assumption.
Our study utilized evidence from all relevant RCTs of 
the prespecified interventions, regardless of whether they 
are in current clinical use. For example, we included trials 
evaluating a single intervention compared with placebo, 
even though neither one is used alone in clinical practice. 
This information increases the power of our analysis86 and, 
although this information is displayed in all results, only 
current combinations of clinical interest may be of use to cli-
nicians. This issue is consistent with pairwise meta-analyses 
in addition to MTC analyses as it allows for increased power 
and determines the magnitude of treatment effects compared 
with inert and less effective interventions.
In conclusion, our study represents the most up-to-date 
analysis of COPD treatments for the reduction of exacerba-
tions that we are aware of. Our study demonstrates consistent 
effects of treatments that increase in combination.
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Appendix 1
Description and WinBUGS implementation of primary 
analysis model. Let A, B, C, D, E, F, G, H, I and J denote 
the treatments placebo, roflumilast, LABA, LAMA, ICS, 
roflumilast + LABA, roflumilast + LAMA, LABA + LAMA, 
ICS + LABA and ICS + LAMA + LABA, respectively. 
Assume that A is the reference (or baseline) treatment for the 
analysis. For each trial j, denote the total number of exac-
erbations in COPD observed for the njk patients allocated to 
treatment k by rjk. Also, let pyjk denote the patient-years of 
follow-up in trial j on treatment k.
Using this notation, the random-effects Poisson regression 
model used in our primary analysis can be expressed as:
rjk ∼ Poisson(λjk) for trial j, treatment k
log( )
log( /)
log( /)
λ jk
jk jA
jk jA jkA
py kA
py k
=
+=
++
1000
1000
µ
µδ
if
if ≠ ≠


 A
δjkA ∼ Normal(dkA, σ  2)
Here, λjk is the expected number of exacerbations in 
COPD in trial j for treatment k and represents the mean of 
the Poisson distribution in trial j under treatment k. Also, µjA 
is the log rate of an exacerbation in COPD in trial j on the 
baseline treatment A, and δjkA is the trial-specific log rate ratio 
of the active treatment k relative to the baseline treatment A. 
These trial-specific log rate ratios are drawn from a random 
effects distribution: δjkA ∼ Normal(dkA, σ  2). The pooled log 
rate ratios dkA for treatment k relative to the baseline treat-
ment A are “baseline” parameters which are used to derive 
the “functional parameters” dkl representing the pooled log 
rate ratios of the active treatment k relative to the active 
treatment l via the consistency equation dkl = dlA − dkA. The 
between-study variance σ2 is a heterogeneity parameter that 
quantifies the extent of the variation between the results 
of the different studies included in the analysis. Note that 
this variance is assumed constant for all pairwise treatment 
comparisons.
The above model was fitted to the data using WinBUGS 
(Version 1.4; MRC Biostatistics Unit). For this model, 
two MCMC chains were run for 100,000 iterations after a 
‘burn-in’ of 20,000 in order to ensure convergence of the 
MCMC sampler. Posterior inference was conducted after 
discarding the ‘burn-in’ iterations, based on 20,000 samples. 
The prior distributions placed on parameters in this model 
were vague and were specified as follows:
µjA ∼ Normal(0, 10000)
dkA ∼ Normal(0, 10000)
σ ∼ Uniform(0, 10)Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Appendix Table 1 Estimated rate ratios and associated 95% Ci 
for the relative effects of pairs of treatments for the management 
of  COPD,  produced  by  the  fixed-effect  MTC  model  without 
covariates
Treatment vs comparator Fixed-effect MTC 
model
Rate ratio 95% CI
Roflumilast vs placebo 0.85 (0.81, 0.89)
LABA vs placebo 0.83 (0.81, 0.86)
LAMA vs placebo 0.81 (0.79, 0.83)
iCs vs placebo 0.79 (0.77, 0.82)
Roflumilast + LABA vs placebo 0.66 (0.58, 0.76)
Roflumilast + LAMA vs placebo 0.68 (0.58, 0.79)
LABA + LAMA vs placebo 0.87 (0.72, 1.05)
iCs + LABA vs placebo 0.70 (0.68, 0.72)
iCs + LAMA + LABA vs placebo 0.74 (0.60, 0.90)
LABA vs roflumilast 0.98 (0.93, 1.04)
LAMA vs roflumilast 0.96 (0.91, 1.01)
ICS vs roflumilast 0.93 (0.88, 0.99)
Roflumilast + LABA vs roflumilast 0.78 (0.68, 0.90)
Roflumilast + LAMA vs roflumilast 0.80 (0.68, 0.94)
LABA + LAMA vs roflumilast 1.03 (0.85, 1.24)
iCs + LABA vs roflumilast 0.82 (0.78, 0.87)
iCs + LAMA + LABA vs roflumilast 0.88 (0.71, 1.07)
LAMA vs LABA 0.97 (0.94, 1.01)
iCs vs LABA 0.95 (0.92, 0.98)
Roflumilast + LABA vs LABA 0.79 (0.70, 0.90)
Roflumilast + LAMA vs LABA 0.82 (0.70, 0.95)
LABA + LAMA vs LABA 1.05 (0.87, 1.26)
iCs + LABA vs LABA 0.84 (0.81, 0.87)
iCs + LAMA + LABA vs LABA 0.89 (0.73, 1.08)
iCs vs LAMA 0.98 (0.94, 1.01)
Roflumilast + LABA vs LAMA 0.82 (0.71, 0.93)
Roflumilast + LAMA vs LAMA 0.84 (0.72, 0.97)
LABA + LAMA vs LAMA 1.08 (0.89, 1.29)
iCs + LABA vs LAMA 0.86 (0.83, 0.89)
iCs + LAMA + LABA vs LAMA 0.92 (0.75, 1.11)
Roflumilast + LABA vs iCs 0.84 (0.73, 0.96)
Roflumilast + LAMA vs iCs 0.86 (0.73, 1.00)
LABA + LAMA vs iCs 1.11 (0.91, 1.33)
iCs + LABA vs iCs 0.88 (0.85, 0.92)
iCs + LAMA + LABA vs iCs 0.94 (0.76, 1.14)
Roflumilast + LAMA vs roflumilast + LABA 1.03 (0.83, 1.25)
LABA + LAMA vs roflumilast + LABA 1.33 (1.05, 1.66)
iCs + LABA vs roflumilast + LABA 1.06 (0.92, 1.21)
LAMA + iCs + LABA vs roflumilast + LABA 1.13 (0.88, 1.42)
LABA + LAMA vs roflumilast + LAMA 1.29 (1.02, 1.64)
iCs + LABA vs roflumilast + LAMA 1.03 (0.89, 1.21)
iCs + LAMA + LABA vs roflumilast + LAMA 1.10 (0.85, 1.40)
iCs + LABA vs LABA + LAMA 0.81 (0.66, 0.97)
iCs + LAMA + LABA vs LABA + LAMA 0.85 (0.70, 1.03)
iCs + LAMA + LABA vs iCs + LABA 1.06 (0.87, 1.29)
Note: A rate ratio smaller (larger) than 1 indicates that the treatment is associated 
with a reduction (increase) in the rate of exacerbations in COPD relative to the 
comparator.
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  iCs,  inhaled 
corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic 
drugs; MTC, mixed-treatment comparison.
Appendix Table 2 Absolute treatment effects corresponding 
to the 10 treatments for the management of COPD, as derived 
from the fixed-effect MTC model without covariates
Treatment Absolute treatment effect 95% CI
Placebo 1.17  (1.15, 1.20)
Roflumilast 0.99  (0.94, 1.04)
LABA 0.98  (0.95, 1.02)
LAMA 0.96  (0.93, 0.99)
iCs 0.94  (0.90, 0.97)
Roflumilast + LABA 0.78  (0.68, 0.89)
Roflumilast + LAMA 0.80  (0.69, 0.93)
LABA + LAMA 0.97  (0.81, 1.15)
iCs + LABA  0.82  (0.80, 0.85)
iCs + LAMA + LABA 0.71  (0.60, 0.84)
Note: Absolute treatment effects are expressed as mean exacerbations experienced 
per patient per patient-year.
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary 
disease; iCs, inhaled corticosteroids; LABA, long-acting beta agonists; LAMA, long-
acting antimuscarinic drugs; MTC, mixed-treatment comparison.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Appendix Table 3 Probability that each of the 10 treatments for management of COPD is best, obtained on the basis of the fixed-effect 
MTC model without covariates
Treatment P1 P2 P3 P4 P5 P6 P7 P8 P9 P10
Placebo 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.071 0.928
Roflumilast 0.000 0.000 0.000 0.002 0.016 0.061 0.191 0.426 0.304 0.000
LABA 0.000 0.000 0.000 0.001 0.016 0.121 0.409 0.357 0.096 0.000
LAMA 0.000 0.000 0.000 0.019 0.199 0.506 0.240 0.032 0.003 0.000
iCs 0.000 0.000 0.007 0.239 0.531 0.189 0.032 0.002 0.000 0.000
Roflumilast + LABA 0.502 0.279 0.145 0.065 0.008 0.001 0.000 0.000 0.000 0.000
Roflumilast + LAMA 0.335 0.284 0.219 0.130 0.020 0.005 0.003 0.002 0.001 0.000
LABA + LAMA 0.000 0.003 0.009 0.032 0.120 0.066 0.081 0.109 0.508 0.072
iCs + LABA 0.056 0.305 0.473 0.161 0.005 0.000 0.000 0.000 0.000 0.000
iCs + LAMA + LABA 0.106 0.128 0.146 0.352 0.084 0.052 0.044 0.070 0.017 0.001
Note: P1–P10 refers to probability that each is 1st, 2nd, … k best.
Abbreviations: COPD, chronic obstructive pulmonary disease; iCs, inhaled corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic drugs; 
MTC, mixed-treatment comparison.
Appendix Table 4 Estimated relative risks and 95% confidence 
intervals for all pairs of treatments produced by the random-
effects MTC model without covariates. Binomial model
Treatment vs comparator Random-effects MTC 
model
Relative risk 95% CI
Roflumilast vs placebo 0.90 (0.79, 0.97)
LABA vs placebo 0.88 (0.79, 0.96)
LAMA vs placebo 0.83 (0.75, 0.90)
iCs vs placebo 0.79 (0.68, 0.89)
Roflumilast + LABA vs placebo 0.74 (0.53, 0.96)
Roflumilast + LAMA vs placebo 0.63 (0.44, 0.85)
LABA + LAMA vs placebo 0.77 (0.56, 1.00)
iCs + LABA vs placebo 0.78 (0.69, 0.87)
iCs + LAMA + LABA vs placebo 0.72 (0.48, 1.00)
LABA vs roflumilast 0.97 (0.82, 1.12)
LAMA vs roflumilast 0.92 (0.77, 1.06)
ICS vs roflumilast 0.88 (0.71, 1.03)
Roflumilast + LABA vs roflumilast 0.82 (0.57, 1.09)
Roflumilast + LAMA vs roflumilast 0.70 (0.47, 0.97)
LABA + LAMA vs roflumilast 0.86 (0.60, 1.14)
iCs + LABA vs roflumilast 0.87 (0.71, 1.02)
iCs + LAMA + LABA vs roflumilast 0.80 (0.52, 1.13)
LAMA vs LABA 0.94 (0.82, 1.07)
iCs vs LABA 0.89 (0.76, 1.02)
Roflumilast + LABA vs LABA 0.83 (0.60, 1.09)
Roflumilast + LAMA vs LABA 0.70 (0.47, 0.99)
LABA + LAMA vs LABA 0.87 (0.61, 1.18)
iCs + LABA vs LABA 0.88 (0.78, 0.98)
(Continued)
Appendix Table 4 (Continued)
Treatment vs comparator Random-effects MTC 
model
Relative risk 95% CI
iCs + LAMA + LABA vs LAMA 0.81 (0.51, 1.18)
iCs vs LAMA 0.96 (0.84, 1.07)
Roflumilast + LABA vs LAMA 0.90 (0.68, 1.14)
Roflumilast + LAMA vs LAMA 0.79 (0.58, 1.02)
LABA + LAMA vs LAMA 0.94 (0.72, 1.17)
iCs + LABA vs LAMA 0.95 (0.85, 1.05)
iCs + LAMA + LABA vs LAMA 0.89 (0.63, 1.16)
Roflumilast + LABA vs iCs 0.93 (0.62, 1.31)
Roflumilast + LAMA vs iCs 0.77 (0.49, 1.14)
LABA + LAMA vs iCs 0.99 (0.65, 1.40)
iCs + LABA vs iCs 0.99 (0.83, 1.17)
iCs + LAMA + LABA vs iCs 0.91 (0.55, 1.40)
Roflumilast + LAMA vs roflumilast + LABA 0.86 (0.51, 1.31)
LABA + LAMA vs roflumilast + LABA 1.07 (0.66, 1.55)
iCs + LABA vs roflumilast + LABA 1.08 (0.77, 1.42)
LAMA + iCs + LABA vs roflumilast + LABA 1.00 (0.57, 1.53)
LABA + LAMA vs roflumilast + LAMA 1.27 (0.77, 1.88)
iCs + LABA vs roflumilast + LAMA 1.28 (0.87, 1.76)
iCs + LAMA + LABA vs roflumilast + LAMA 1.19 (0.67, 1.84)
iCs + LABA vs LABA + LAMA 1.02 (0.72, 1.36)
iCs + LAMA + LABA vs LABA + LAMA 0.94 (0.62, 1.32)
iCs + LAMA + LABA vs iCs + LABA 0.93 (0.61, 1.30)
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  iCs,  inhaled 
corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic 
drugs; MTC, mixed-treatment comparison.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Appendix Table 5 Absolute treatment effects obtained from 
the random-effects MTC model on binomial model
Treatment Absolute treatment effect 95% CI
Placebo 0.35 (0.33, 0.36)
Roflumilast 0.31 (0.27, 0.36)
LABA 0.30 (0.27, 0.33)
LAMA 0.28 (0.25, 0.31)
iCs 0.26 (0.23, 0.30)
Roflumilast + LABA 0.25 (0.17, 0.33)
Roflumilast + LAMA 0.21 (0.14, 0.29)
LABA + LAMA 0.26 (0.18, 0.35)
iCs + LABA 0.26 (0.23, 0.29)
iCs + LAMA + LABA 0.24 (0.15, 0.35)
Note: Absolute treatment effects are expressed as mean exacerbations experienced 
per patient per patient-year.
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  iCs,  inhaled 
corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic 
drugs; MTC, mixed-treatment comparison.
Appendix Table 6 Probability each of the 10 treatments for 
management  of  COPD  is  best,  obtained  on  the  basis  of  the 
random-effects MTC model without covariates. Binomial model
Treatment Probability treatment is best
Placebo 0.000
Roflumilast 0.000
LABA 0.000 
LAMA 0.000
iCs 0.011
Roflumilast + LABA 0.147
Roflumilast + LAMA 0.562
LABA + LAMA 0.061
iCs + LABA 0.010
iCs + LAMA + LABA 0.207
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  iCs,  inhaled 
corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic 
drugs; MTC, mixed-treatment comparison.
Appendix  Table  7  random  effects,  direct  (head  to  head) 
evaluation  using  Dersimmonian  Laird  random-effects  model. 
Exacerbation rates
Treatment vs Comparator Random-effects direct 
evidence
Rate ratio 95% CI
Roflumilast vs placebo 0.85 (0.78–0.93)
LABA vs placebo 0.87 (0.79–0.96)
LAMA vs placebo 0.74 (0.64–0.84)
iCs vs placebo 0.81 (0.74–0.90)
iCs + LABA vs placebo 0.72 (0.66–0.79)
LAMA vs LABA 0.91 (0.80–1.06)
Roflumilast + LABA vs LABA 0.79 (0.70–0.91)
iCs + LABA vs LABA 0.81 (0.75–0.86)
iCs + LABA + LAMA vs LAMA 0.91 (0.75–1.11)
Roflumilast + LAMA vs LAMA 0.83 (0.72–0.97)
LABA + LAMA vs LAMA 1.07 (0.94–1.22)
iCs + LABA vs LAMA 0.97 (0.93–1.02)
iCs + LABA + LAMA vs LABA + LAMA 0.85 (0.74–0.97)
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  iCs,  inhaled 
corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic 
drugs; MTC, mixed-treatment comparison.
Appendix  Table  8  random  effects,  direct  (head  to  head) 
evaluation  using  Dersimmonian  Laird  random-effects  model. 
Binomial model
Treatment vs comparator Random-effects direct 
evidence
Relative risk 95% CI
Roflumilast vs placebo 0.90 (0.85–0.95)
LABA vs placebo 0.85 (0.78–0.91)
LAMA vs placebo 0.84 (0.77–0.92)
iCs vs placebo 0.69 (0.57–0.83)
iCs + LABA vs placebo 0.70 (0.57–0.88)
LAMA vs LABA 0.95 (0.82–1.10)
Roflumilast + LABA vs LABA 0.83 (0.83–1.00)
iCs + LABA vs LABA 0.90 (0.83–0.98)
iCs + LABA + LAMA vs LAMA 0.96 (0.80–1.14)
Roflumilast + LAMA vs LAMA 0.73 (0.62–0.87)
LABA + LAMA vs LAMA 0.83 (0.46–1.51)
iCs + LABA vs LAMA 1.05 (0.96–1.15)
iCs + LABA + LAMA vs LABA + LAMA 0.93 (0.82–1.05)
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  iCs,  inhaled 
corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic 
drugs; MTC, mixed-treatment comparison.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Appendix Table 10 Absolute treatment effects obtained from 
the random-effects MTC model including previously unpublished 
roflumilast data (M2-111 trial)28
Treatment Absolute treatment effect (95% CI)
Original MTC analysis
Placebo 1.18 (1.15, 1.21)
Roflumilast 0.98 (0.83, 1.15)
LABA 0.98 (0.89, 1.09)
LAMA 0.87 (0.78, 0.95)
iCs 0.94 (0.84, 1.05)
Roflumilast + LABA 0.79 (0.57, 1.07)
Roflumilast + LAMA 0.73 (0.53, 1.00)
LABA + LAMA 0.94 (0.66, 1.31)
iCs + LABA 0.81 (0.72, 0.90)
iCs + LAMA + LABA 0.80 (0.56, 1.11)
Note: Absolute treatment effects are expressed as mean exacerbations experienced 
per patient per patient-year.
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  iCs,  inhaled 
corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic 
drugs; MTC, mixed-treatment comparison.
Appendix Table 9 Estimated rate ratios and associated 95% Ci 
for the relative effects of pairs of treatments for the management 
of COPD, produced by random effects MTC involving previously 
unpublished roflumilast data (M2-111 trial)28
Treatment vs comparator Rate ratio (95% CI)
Original MTC analysis
Roflumilast vs placebo 0.83 (0.70, 0.97)
LABA vs placebo 0.84 (0.75, 0.93)
LAMA vs placebo 0.74 (0.66, 0.81)
iCs vs placebo 0.80 (0.71, 0.89)
Roflumilast + LABA vs placebo 0.67 (0.48, 0.91)
Roflumilast + LAMA vs placebo 0.62 (0.45, 0.84)
LABA + LAMA vs placebo 0.80 (0.56, 1.11)
iCs + LABA vs placebo 0.69 (0.61, 0.77)
iCs + LAMA + LABA vs placebo 0.68 (0.47, 0.94)
LABA vs roflumilast 1.01 (0.83, 1.23)
LAMA vs roflumilast 0.89 (0.73, 1.07)
ICS vs roflumilast 0.97 (0.79, 1.18)
Roflumilast + LABA vs roflumilast 0.81 (0.56, 1.14)
Roflumilast + LAMA vs roflumilast 0.75 (0.52, 1.06)
LABA + LAMA vs roflumilast 0.97 (0.65, 1.39)
iCs + LABA vs roflumilast 0.83 (0.68, 1.01)
iCs + LAMA + LABA vs roflumilast 0.82 (0.55, 1.18)
LAMA vs LABA 0.88 (0.77, 1.01)
iCs vs LABA 0.96 (0.84, 1.08)
Roflumilast + LABA vs LABA 0.80 (0.59, 1.07)
Roflumilast + LAMA vs LABA 0.74 (0.53, 1.02)
LABA + LAMA vs LABA 0.96 (0.67, 1.34)
iCs + LABA vs LABA 0.82 (0.74, 0.91)
iCs + LAMA + LABA vs LABA 0.82 (0.56, 1.14)
iCs vs LAMA 1.09 (0.93, 1.26)
Roflumilast + LABA vs LAMA 0.91 (0.65, 1.25)
Roflumilast + LAMA vs LAMA 0.84 (0.62, 1.13)
LABA + LAMA vs LAMA 1.09 (0.78, 1.48)
iCs + LABA vs LAMA 0.94 (0.81, 1.07)
iCs + LAMA + LABA vs LAMA 0.92 (0.65, 1.27)
Roflumilast + LABA vs iCs 0.84 (0.61, 1.15)
Roflumilast + LAMA vs iCs 0.78 (0.55, 1.08)
LABA + LAMA vs iCs 1.00 (0.69, 1.41)
iCs + LABA vs iCs 0.86 (0.76, 0.98)
iCs + LAMA + LABA vs iCs 0.85 (0.59, 1.21)
Roflumilast + LAMA vs roflumilast + LABA 0.95 (0.59, 1.45)
LABA + LAMA vs roflumilast + LABA 1.22 (0.76, 1.89)
iCs + LABA vs roflumilast + LABA 1.05 (0.76, 1.42)
LAMA + iCs + LABA vs roflumilast + LABA 1.04 (0.64, 1.61)
LABA + LAMA vs roflumilast + LAMA 1.32 (0.83, 1.99)
iCs + LABA vs roflumilast + LAMA 1.14 (0.80, 1.55)
iCs + LAMA + LABA vs roflumilast + LAMA 1.12 (0.70, 1.71)
iCs + LABA vs LABA + LAMA 0.88 (0.61, 1.23)
iCs + LAMA + LABA vs LABA + LAMA 0.86 (0.61, 1.18)
iCs + LAMA + LABA vs iCs + LABA 0.99 (0.68, 1.40)
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  iCs,  inhaled 
corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic 
drugs; MTC, mixed-treatment comparison.
Appendix  Table  11  Probability  each  of  the  15  treatments 
(ie, 5 single treatments plus 10 combinations of active treatments) 
for management of COPD is best, obtained on the basis of the 
additive main effects model considered in our secondary MTC 
analysis.  This  table  includes  previously  unpublished  roflumilast 
data (M2-111 trial)28
Treatment Probability treatment is best
Placebo 0.000
Roflumilast 0.000
LABA 0.000
LAMA 0.000
iCs 0.000
Roflumilast + LABA 0.000
Roflumilast + LAMA 0.000
Roflumilast + iCs 0.000
LABA + LAMA 0.000
LABA + iCs 0.000
LAMA + iCs 0.000
Roflumilast + LABA + LAMA 0.000
Roflumilast + LABA + iCs 0.000
LAMA + LABA + iCs 0.003
Roflumilast + LABA + LAMA + iCs 0.997
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  iCs,  inhaled 
corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic 
drugs; MTC, mixed-treatment comparison.Clinical Epidemiology
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Appendix Table 12 Estimated rate ratios and 95% Ci for the 
effects of specific pairs of treatment combinations, produced by 
the additive main effects model considered in our MTC analysis 
including previously unpublished data (M2-111)28
Treatment vs comparator Additive main effects 
model
Rate ratio 95% CI
LABA plus ICS plus roflumilast vs 
LABA plus iCs
0.82 0.73–0.93
LABA plus iCs plus LAMA vs 
LABA plus ICS plus roflumilast
0.90 0.77–1.05
LABA plus iCs plus LAMA plus 
roflumilast vs LABA plus ICS plus LAMA
0.82 0.73–0.93
LAMA plus LABA plus roflumilast vs 
LABA plus LAMA
0.82 0.73–0.93
LAMA plus LABA plus iCs vs 
LAMA plus LABA plus roflumilast 
1.00 0.86–1.15
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  iCs,  inhaled 
corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic 
drugs; MTC, mixed-treatment comparison.